Trial Profile
A Double Blind Randomised Comparison of Vorapaxar Versus Placebo for the Treatment of HIV Associated Inflammation and Coagulopathy in Patients With Well Controlled HIV Replication
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 14 May 2022
Price :
$35
*
At a glance
- Drugs Vorapaxar (Primary)
- Indications Blood coagulation disorders; Inflammation
- Focus Therapeutic Use
- Acronyms ADVICE
- 05 Feb 2019 Status changed from recruiting to completed.
- 20 Jun 2017 Planned End Date changed from 1 Nov 2017 to 1 Dec 2017.
- 20 Jun 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Dec 2017.